Challenges in the development of effective peptide vaccines for cancer

Chantal Buteau, Svetomir N. Markovic, Esteban Celis

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

The ability of the immune system to recognize malignant cells has opened the door to development of tumor vaccines to treat or prevent various types of cancer. In the era of molecular biology, the tumor antigens recognized by the immune system have been identified, allowing the generation of subunit vaccines that may improve safety and efficacy compared with more crude vaccines such as irradiated tumor cells and tumor cell lysates. Synthetic peptides corresponding to defined antigenic epitopes for tumor-reactive lymphocytes represent one of the new types of vaccines currently being developed to treat or prevent various types of malignant disorders. The design of peptide-based vaccines to stimulate antitumor T-cell responses has many attractive features such as ease of manufacturing and characterization (ie, quality control), as well as an excellent safety profile in past clinical studies. However, ambiguous results from initial clinical trials indicate that these vaccines are far from optimal and that considerable efforts for their optimization lie ahead. We attempt to address the 8 most important challenges we currently face for developing peptide-based vaccines that would effectively induce immune responses leading to antitumor effects.

Original languageEnglish (US)
Article number61787
Pages (from-to)339-349
Number of pages11
JournalMayo Clinic Proceedings
Volume77
Issue number4
DOIs
StatePublished - Jan 1 2002

Fingerprint

Subunit Vaccines
Vaccines
Immune System
Neoplasms
Safety
Cancer Vaccines
Neoplasm Antigens
Quality Control
Epitopes
Molecular Biology
Clinical Trials
Lymphocytes
T-Lymphocytes
Peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Challenges in the development of effective peptide vaccines for cancer. / Buteau, Chantal; Markovic, Svetomir N.; Celis, Esteban.

In: Mayo Clinic Proceedings, Vol. 77, No. 4, 61787, 01.01.2002, p. 339-349.

Research output: Contribution to journalReview article

Buteau, Chantal ; Markovic, Svetomir N. ; Celis, Esteban. / Challenges in the development of effective peptide vaccines for cancer. In: Mayo Clinic Proceedings. 2002 ; Vol. 77, No. 4. pp. 339-349.
@article{dda01867b5bb46f098b71bb92633ea69,
title = "Challenges in the development of effective peptide vaccines for cancer",
abstract = "The ability of the immune system to recognize malignant cells has opened the door to development of tumor vaccines to treat or prevent various types of cancer. In the era of molecular biology, the tumor antigens recognized by the immune system have been identified, allowing the generation of subunit vaccines that may improve safety and efficacy compared with more crude vaccines such as irradiated tumor cells and tumor cell lysates. Synthetic peptides corresponding to defined antigenic epitopes for tumor-reactive lymphocytes represent one of the new types of vaccines currently being developed to treat or prevent various types of malignant disorders. The design of peptide-based vaccines to stimulate antitumor T-cell responses has many attractive features such as ease of manufacturing and characterization (ie, quality control), as well as an excellent safety profile in past clinical studies. However, ambiguous results from initial clinical trials indicate that these vaccines are far from optimal and that considerable efforts for their optimization lie ahead. We attempt to address the 8 most important challenges we currently face for developing peptide-based vaccines that would effectively induce immune responses leading to antitumor effects.",
author = "Chantal Buteau and Markovic, {Svetomir N.} and Esteban Celis",
year = "2002",
month = "1",
day = "1",
doi = "10.4065/77.4.339",
language = "English (US)",
volume = "77",
pages = "339--349",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Challenges in the development of effective peptide vaccines for cancer

AU - Buteau, Chantal

AU - Markovic, Svetomir N.

AU - Celis, Esteban

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The ability of the immune system to recognize malignant cells has opened the door to development of tumor vaccines to treat or prevent various types of cancer. In the era of molecular biology, the tumor antigens recognized by the immune system have been identified, allowing the generation of subunit vaccines that may improve safety and efficacy compared with more crude vaccines such as irradiated tumor cells and tumor cell lysates. Synthetic peptides corresponding to defined antigenic epitopes for tumor-reactive lymphocytes represent one of the new types of vaccines currently being developed to treat or prevent various types of malignant disorders. The design of peptide-based vaccines to stimulate antitumor T-cell responses has many attractive features such as ease of manufacturing and characterization (ie, quality control), as well as an excellent safety profile in past clinical studies. However, ambiguous results from initial clinical trials indicate that these vaccines are far from optimal and that considerable efforts for their optimization lie ahead. We attempt to address the 8 most important challenges we currently face for developing peptide-based vaccines that would effectively induce immune responses leading to antitumor effects.

AB - The ability of the immune system to recognize malignant cells has opened the door to development of tumor vaccines to treat or prevent various types of cancer. In the era of molecular biology, the tumor antigens recognized by the immune system have been identified, allowing the generation of subunit vaccines that may improve safety and efficacy compared with more crude vaccines such as irradiated tumor cells and tumor cell lysates. Synthetic peptides corresponding to defined antigenic epitopes for tumor-reactive lymphocytes represent one of the new types of vaccines currently being developed to treat or prevent various types of malignant disorders. The design of peptide-based vaccines to stimulate antitumor T-cell responses has many attractive features such as ease of manufacturing and characterization (ie, quality control), as well as an excellent safety profile in past clinical studies. However, ambiguous results from initial clinical trials indicate that these vaccines are far from optimal and that considerable efforts for their optimization lie ahead. We attempt to address the 8 most important challenges we currently face for developing peptide-based vaccines that would effectively induce immune responses leading to antitumor effects.

UR - http://www.scopus.com/inward/record.url?scp=0036196269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036196269&partnerID=8YFLogxK

U2 - 10.4065/77.4.339

DO - 10.4065/77.4.339

M3 - Review article

C2 - 11936929

AN - SCOPUS:0036196269

VL - 77

SP - 339

EP - 349

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

M1 - 61787

ER -